Zinc

Zinc is one of the best-replicated micronutrient interventions in global child health. A 2024 systematic review and meta-analysis of 38 RCTs (commissioned by WHO to update its guidelines) found zinc supplementation increased the proportion of children recovered from acute diarrhea at last follow-up (RR 1.07, 95% CI 1.03–1.10) and shortened diarrhea duration by roughly 13 hours (MD −13.27 h; moderate-certainty evidence) ^{4Reference 4Ali et al. · 2024Meta-analysisZinc supplementation for acute and persistent watery diarrhoea in children: a systematic review and meta-analysis — [meta-analysis]View study →}.

An earlier meta-analysis pooling trials across 10 countries (18,822 cases) found a similar direction of effect ^{5Reference 5Lamberti et al. · 2013Meta-analysisOral zinc supplementation for the treatment of acute diarrhea in children — [systematic review and meta-analysis]View study →}.

The benefit is concentrated in low- and middle-income settings where baseline zinc status is often marginal to deficient; vomiting was more common in the zinc arm ^{4Reference 4Ali et al. · 2024Meta-analysisZinc supplementation for acute and persistent watery diarrhoea in children: a systematic review and meta-analysis — [meta-analysis]View study →}.

Gap: almost all supporting trials are in children in low-resource settings with meaningful baseline deficiency risk — this is a repletion effect, not evidence that zinc treats diarrhea in a zinc-replete adult.

The original Age-Related Eye Disease Study (AREDS) randomized 3,640 participants aged 55–80 with existing drusen or AMD in at least one eye to antioxidants (vitamin C, E, beta carotene), zinc (80 mg as zinc oxide, with 2 mg copper), both, or placebo, and followed them for an average of 6.3 years ^{7Reference 7Age-Related Eye Disease Study Research G · 2001RCTHigh-dose vitamins C and E, beta carotene, and zinc for age-related macular degeneration: AREDS report noView study →}.

Antioxidants plus zinc significantly reduced the odds of progression to advanced AMD versus placebo (OR 0.72, 99% CI 0.52–0.98), with zinc alone showing a similar but not independently significant trend ^{7Reference 7Age-Related Eye Disease Study Research G · 2001RCTHigh-dose vitamins C and E, beta carotene, and zinc for age-related macular degeneration: AREDS report noView study →}.

The benefit was concentrated in participants who already had higher-risk drusen or pigment changes — those with minimal disease had only a 1.3% five-year progression risk regardless of treatment ^{7Reference 7Age-Related Eye Disease Study Research G · 2001RCTHigh-dose vitamins C and E, beta carotene, and zinc for age-related macular degeneration: AREDS report noView study →}.

The follow-on AREDS2 trial confirmed the zinc/antioxidant combination’s role while testing lutein/zeaxanthin as a beta-carotene substitute ^{8Reference 8Age-Related Eye Disease Study 2 Research · 2013RCTLutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial — [RCT]View study →}, and a 2023 Cochrane review supports the AREDS-type formula’s effect on slowing progression to advanced disease ^{9Reference 9Evans et al. · 2023Systematic reviewAntioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration — [Cochrane systematic review]View study →}.

Gap: this evidence is specific to people who already have intermediate-to-large drusen or pigment abnormalities — it is not evidence that zinc prevents AMD from developing in the first place, and the 80 mg/day zinc dose used in AREDS is twice the adult Tolerable Upper Intake Level.

A 2019 meta-analysis of 32 placebo-controlled interventions (1,700 participants, 14 countries) found zinc supplementation significantly reduced fasting glucose (WMD −14.15 mg/dL), 2-hour postprandial glucose, fasting insulin, HOMA-IR, HbA1c (WMD −0.55%), and hs-CRP versus control, with effects influenced by baseline diabetic status and by whether the zinc formulation was organic or inorganic ^{10Reference 10Wang et al. · 2019Meta-analysisZinc supplementation improves glycemic control for diabetes prevention and management — [systematic review and meta-analysis]View study →}.

A 2024 GRADE-assessed dose-response meta-analysis in people with prediabetes and type 2 diabetes reported similar cardiometabolic benefits ^{11Reference 11Nazari et al. · 2024Meta-analysisZinc supplementation in individuals with prediabetes and type 2 diabetes: a GRADE-assessed systematic review and dose-response meta-analysis — [meta-analysis]View study →}.

Effect sizes are moderate and heterogeneous across formulations and doses, and most trial populations already have impaired glucose handling.

Gap: benefit is largest in people with diabetes or prediabetes; there isn’t good evidence this moves glycemic markers in metabolically healthy, zinc-replete adults.

A Cochrane review of RCTs in children aged 2–59 months found zinc supplementation reduced the incidence of pneumonia, with the effect most apparent in populations with a higher baseline burden of zinc deficiency and undernutrition ^{6Reference 6Lassi et al. · 2016Systematic reviewZinc supplementation for the prevention of pneumonia in children aged 2–59 months — [Cochrane systematic review]View study →}. Related meta-analyses of lower respiratory tract infection show a similar pattern: benefit tracks with deficiency prevalence in the study population rather than being a universal immune enhancer.

Gap: conducted almost entirely in developing-country pediatric cohorts with elevated deficiency risk; not evidence for using zinc to prevent respiratory infection in a well-nourished adult.

This is the most contested application in the zinc literature. Individual-patient-data meta-analyses of zinc acetate lozenge trials found colds resolved roughly 2.7–2.9 days faster than placebo ^{1Reference 1Hemilä · 2016Meta-analysisZinc acetate lozenges for treating the common cold: an individual patient data meta-analysis — [meta-analysis]View study →}, regardless of allergy status, smoking, age, or sex within the pooled dataset ^{1Reference 1Hemilä · 2016Meta-analysisZinc acetate lozenges for treating the common cold: an individual patient data meta-analysis — [meta-analysis]View study →}.

But a rigorously blinded confirmatory RCT of a commercially available 13 mg zinc-acetate lozenge (6×/day) found no difference in cold recovery rate versus placebo, and recovery was actually slower in the zinc group for two days after treatment stopped, with substantial unblinding from the distinctive metallic taste ^{3Reference 3Hemilä · 2020RCTZinc acetate lozenges for the treatment of the common cold: a randomised controlled trial — [RCT, null]View study →}.

A 2024 Cochrane update (34 RCTs, 8,526 participants) concluded there is probably little or no difference in cold duration (MD −0.63 day, 95% CI −1.29 to 0.04; moderate-certainty), while noting a possible reduction specifically in treatment (not prevention) trials (MD −2.37 days; low-certainty, high heterogeneity) ^{2Reference 2Nault et al. · 2024Systematic reviewZinc for prevention and treatment of the common cold — [Cochrane systematic review]View study →}.

The lead author of the earlier positive meta-analyses has publicly disputed the 2024 Cochrane review’s methodology.

Gap: effect size and even direction vary by lozenge formulation (acetate vs gluconate), dose, and trial; taste-driven unblinding is a persistent confound; there is no dietary-source equivalent of this effect — it depends on a specific pharmaceutical lozenge form dosed from symptom onset.

A systematic review and meta-analysis found people with acne have significantly lower serum zinc than controls, and zinc treatment (oral or topical, as monotherapy or adjunct) produced a significant reduction in inflammatory papule count with no significant excess of side effects versus comparators ^{12Reference 12Yee et al. · 2020Meta-analysisSerum zinc levels and efficacy of zinc treatment in acne vulgaris: a systematic review and meta-analysis — [meta-analysis]View study →}. Effect sizes are modest and most positive trials are small; major dermatology guidance treats zinc as a second-line or adjunct option rather than a primary acne therapy.

Gap: the serum-zinc-is-lower-in-acne-patients association doesn’t establish deficiency as the cause, and most positive trials are underpowered by modern standards.

Zinc is required for collagen synthesis, cell proliferation, and the local immune response at a wound site, and a substantial mechanistic and clinical literature documents impaired healing in zinc-deficient states along with normalization on repletion ^{13Reference 13Lansdown et al. · 2007ReviewZinc in wound healing: theoretical, experimental, and clinical aspects — [review]View study →}. Randomized trial evidence in adults who are not zinc-deficient is comparatively sparse; most positive clinical data comes from populations with a plausible existing deficiency (chronic wounds, older adults, malnutrition).

Gap: this is well-supported as a corrective — treating a deficiency that is slowing healing — not as a booster that speeds healing in someone already zinc-replete.

A meta-analysis of observational and RCT data found lower zinc status associated with depression and some benefit of supplementation ^{14Reference 14Swardfager et al. · 2013Meta-analysisZinc in depression: a meta-analysis — [meta-analysis]View study →}.

A more recent RCT-focused systematic review found zinc combined with antidepressant drugs produced a modest reduction in depressive symptoms versus placebo (SMD −0.36, 95% CI −0.67 to −0.04), with a larger effect in trials of participants averaging 40+ years old — but the conclusion explicitly limited the benefit to zinc used alongside antidepressant treatment, not as a standalone intervention ^{15Reference 15da Silva et al. · 2021Meta-analysisZinc supplementation combined with antidepressant drugs for treatment of patients with depression: a systematic review and meta-analysis — [meta-analysis]View study →}.

A separate meta-analysis of zinc’s effect on brain-derived neurotrophic factor (BDNF), one proposed mechanism, found no significant increase in BDNF with supplementation across five small studies ^{16Reference 16Jafari et al. · 2021Meta-analysisThe effect of zinc supplementation on brain-derived neurotrophic factor: a meta-analysis — [meta-analysis]View study →}.

Gap: the number of qualifying RCTs is small, and the proposed BDNF mechanism doesn’t hold up under its own meta-analysis — treat this as a modest adjunct signal, not evidence zinc treats depression on its own.

The testosterone-boosting reputation traces largely to studies in deficient or diseased men. In male hemodialysis patients — a population with well-documented low zinc status — six weeks of zinc sulfate (250 mg/day) significantly raised serum testosterone and LH ^{17Reference 17Jalali et al. · 2010RCTImpact of oral zinc therapy on the level of sex hormones in male patients on hemodialysis — [RCT, deficient population]View study →}.

In men with isolated hypogonadotropic hypogonadism already on hormone replacement, adding oral zinc did not further improve spermatogenesis over 18 months ^{19Reference 19Liu et al. · 2017RCTThe effectiveness of zinc supplementation in men with isolated hypogonadotropic hypogonadism — [RCT]View study →}.

In the largest and most rigorous test in a general (not zinc-deficient) fertility population — a randomized trial of 2,370 couples — daily folic acid plus zinc in men produced no improvement in semen quality or live birth rate versus placebo ^{18Reference 18Schisterman et al. · 2020RCTEffect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment — [RCT, null]View study →}.

The pattern is consistent: zinc raises testosterone and related markers specifically in men who are zinc-deficient or otherwise compromised, with no demonstrated benefit in men whose zinc status and fertility are already normal ^{17,18,19Reference 17Jalali et al. · 2010RCTImpact of oral zinc therapy on the level of sex hormones in male patients on hemodialysis — [RCT, deficient population]View study →Reference 18Schisterman et al. · 2020RCTEffect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment — [RCT, null]View study →Reference 19Liu et al. · 2017RCTThe effectiveness of zinc supplementation in men with isolated hypogonadotropic hypogonadism — [RCT]View study →}.

Gap: the popular “zinc for T” claim is a deficiency-correction effect that has not generalized to replete men; the animal/rat data often cited for a general muscle/hormone effect has no confirmed human mechanism at replete zinc status.